Reaction
Infected Skin Ulcer reporting signals
As of the last recalculation, Infected Skin Ulcer appears in 1,866 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is QUININE (PRR 13.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Quinine | 10 | 13.1 | 13.1 |
| Valganciclovir Hydrochloride Powder, | 12 | 11.0 | 11.0 |
| Canagliflozin | 28 | 10.6 | 10.6 |
| Polatuzumab Vedotin | 9 | 10.3 | 10.3 |
| Valganciclovir | 16 | 9.5 | 9.5 |
| Valganciclovir Hydrochloride | 16 | 9.5 | 9.5 |
| Oxybutynin Chloride | 6 | 7.7 | 7.7 |
| Imatinib | 12 | 7.6 | 7.6 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 20 | 7.2 | 7.3 |
| Bendamustine Hcl | 10 | 7.2 | 7.2 |
| Tocilizumab | 71 | 7.2 | 7.2 |
| Isosorbide Mononitrate | 13 | 7.0 | 7.0 |
| Rotigotine | 9 | 7.0 | 7.0 |
| Bosentan | 31 | 7.0 | 7.0 |
| Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose | 5 | 6.8 | 6.8 |
| Interferon Beta-1B | 11 | 6.4 | 6.4 |
| Dolutegravir Sodium | 5 | 6.2 | 6.2 |
| Ocrelizumab | 31 | 5.7 | 5.7 |
| Diclofenac Potassium, Film Coated | 4 | 5.3 | 5.3 |
| Diclofenac Potassium Tablets | 4 | 5.3 | 5.3 |
| Natalizumab | 83 | 5.3 | 5.3 |
| Peginterferon Beta-1A | 6 | 5.1 | 5.1 |
| Interferon Beta-1A | 84 | 5.0 | 5.0 |
| Gemcitabine | 17 | 4.8 | 4.9 |
| Golimumab | 35 | 4.6 | 4.6 |
| Diclofenac Potassium | 4 | 4.1 | 4.1 |
| Abiraterone | 5 | 4.1 | 4.1 |
| Voxelotor | 7 | 3.5 | 3.5 |
| Tafamidis | 3 | 2.8 | 2.8 |
| Cabozantinib | 12 | 2.8 | 2.8 |
| Sarilumab | 6 | 2.5 | 2.5 |
| Patiromer | 3 | 2.4 | 2.4 |
| Pimavanserin Tartrate | 6 | 1.2 | 1.2 |
| Cinacalcet Hydrochloride | 5 | 1.2 | 1.2 |
| Salicylic Acid | 3 | 0.6 | 0.6 |